{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:10:37Z","timestamp":1789996237457,"version":"4.0.1"},"reference-count":38,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Timely development and approval of innovative drugs are essential for patient access and public health. China has implemented regulatory reforms, including priority review and conditional approval, to accelerate drug development. We conducted a cross\u2010sectional study of 232 innovative drugs, comprising chemical drugs, biologics, and traditional Chinese medicines (\n                    <jats:styled-content style=\"fixed-case\">TCMs<\/jats:styled-content>\n                    ), approved by the National Medical Products Administration during 2010\u20132025. Development timelines for 227 drugs were analyzed using generalized linear models with a gamma distribution and log link to assess associations with drug type, regulatory pathways, orphan drug status, reform stage, indication, primary endpoint duration, and sample size. Median total development time was 6.94\u2009years (\n                    <jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>\n                    , 4.85\u20139.97), with biologics having the shortest duration (5.14\u2009years) and\n                    <jats:styled-content style=\"fixed-case\">TCMs<\/jats:styled-content>\n                    the longest (10.22\u2009years). Drug type and conditional approval were primary variables associated with total development time. Conditional approval was associated with shorter total development time among oncology drugs (relative mean ratio [\n                    <jats:styled-content style=\"fixed-case\">RMR<\/jats:styled-content>\n                    ]\u2009=\u20090.66,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), with a significant interaction by indication (\n                    <jats:styled-content style=\"fixed-case\">RMR<\/jats:styled-content>\n                    \u2009=\u20092.08,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Among drugs not receiving conditional approval, clinical development time was longer in later reform stages by up to 52%, whereas marketing application review time decreased in later reform stages overall, with a 64% reduction in Stage\n                    <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content>\n                    (\n                    <jats:styled-content style=\"fixed-case\">RMR<\/jats:styled-content>\n                    \u2009=\u20090.36,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Priority review and conditional approval were associated with 26% and 28% reductions in review time, respectively (both\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05). These findings suggest heterogeneous associations of China's regulatory reforms across pathways and therapeutic areas, consistent with differential contributions of administrative acceleration and evidentiary modification to development timelines.\n                  <\/jats:p>","DOI":"10.1111\/cts.70702","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:31:28Z","timestamp":1788262288000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development Timelines of Innovative Drugs in China: A 15\u2010Year Cross\u2010Sectional Analysis of Characteristics and Influencing Factors"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3093-5824","authenticated-orcid":false,"given":"Meimei","family":"Xu","sequence":"first","affiliation":[{"name":"Institute of Medical Information, Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8430-4045","authenticated-orcid":false,"given":"Chenpeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Medical Information, Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9870-7009","authenticated-orcid":false,"given":"Xinying","family":"An","sequence":"additional","affiliation":[{"name":"Institute of Medical Information, Chinese Academy of Medical Sciences and Peking Union Medical College  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-021-00190-9"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100983"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100998"},{"key":"e_1_2_9_5_1","first-page":"2074","article-title":"Insights Into Changes to the Priority Review System From the Perspective of the New Provisions for Drug Registration in China","volume":"55","author":"Wang J. C.","year":"2020","journal-title":"Chinese Pharmaceutical Journal"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41256-024-00396-5"},{"key":"e_1_2_9_7_1","unstructured":"State Administration for Market Regulation Provisions for Drug Registration https:\/\/www.gov.cn\/zhengce\/zhengceku\/2020\u201004\/01\/content_5498012.htm."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.14896"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13519"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1404922"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-022-00077-3"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S514132"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104240"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02267-y"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1559703"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13020-025-01152-8"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2022.08.004"},{"key":"e_1_2_9_18_1","first-page":"202","article-title":"Overview and Analysis of Rare Disease Drugs Approved for Market in China, the United States, the European Union, and Japan in 2023","volume":"3","author":"Wang S.","year":"2024","journal-title":"Journal of Rare Diseases"},{"key":"e_1_2_9_19_1","unstructured":"State Council Opinions on the Reform of the Review and Approval System for Drugs and Medical Devices https:\/\/www.gov.cn\/zhengce\/content\/2015\u201008\/18\/content_10101.htm."},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2581915"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03084-2"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-6296(01)00086-8"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1992.10475190"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13168-y"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1296737"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1595497"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2014.12.016"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28247941"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53554-7"},{"key":"e_1_2_9_30_1","first-page":"1","article-title":"From Tradition to Evidence\u2010Base: Leveraging TCM Human Use Experience in Modern Drug Development","author":"Lu L.","year":"2024","journal-title":"SSRN Electronic Journal"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-025-04906-x"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-019-2722-2"},{"issue":"10","key":"e_1_2_9_33_1","first-page":"1261","article-title":"Application of Chinese Medical Syndrome Scores in Effectiveness Evaluation: A Critical Appraisal of 240 Randomized Controlled Trials","volume":"35","author":"Luo H.","year":"2015","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"key":"e_1_2_9_34_1","unstructured":"Center for Drug Evaluation NMPA Guideline on the Preparation of Investigational Medicinal Products for Clinical Trials With New Chinese Medicines (Trial Implementation) https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/c36e5f39426b9a402be39c89016ebe7c."},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.09.006"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1501525"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3676"},{"issue":"3","key":"e_1_2_9_38_1","first-page":"217","article-title":"Deepening Regulatory Reform to Promote High\u2010Quality Development of the Pharmaceutical Industry","volume":"27","author":"Li L.","year":"2025","journal-title":"Chinese Journal of Medicinal Guide"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.150"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70702","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.70702","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.70702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:44:38Z","timestamp":1789994678000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.70702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/cts.70702"],"URL":"https:\/\/doi.org\/10.1111\/cts.70702","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2025-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70702"}}